BioXcel Therapeutics Files 8-K on Shareholder Votes

TL;DR

BioXcel Therapeutics held a shareholder vote on Jan 28th. Details in new 8-K.

AI Summary

BioXcel Therapeutics, Inc. filed an 8-K on January 29, 2025, reporting on matters submitted to a vote of security holders as of January 28, 2025. The filing details the company's corporate structure, including its state of incorporation (Delaware) and principal executive offices in New Haven, CT.

Why It Matters

This filing indicates that BioXcel Therapeutics held or is holding a vote of its security holders, which could pertain to significant corporate decisions or governance matters.

Risk Assessment

Risk Level: low — This is a routine filing reporting on a shareholder vote, not indicating any immediate financial distress or significant operational change.

Key Numbers

• 001-38410 — Commission File Number (Identifies the company's SEC filing history)
• 82-1386754 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• BioXcel Therapeutics, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• New Haven, CT (location) — Principal executive offices
• January 28, 2025 (date) — Date of earliest event reported
• January 29, 2025 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 B — registered Common Stock, par value $0.001 BTAI The Nasdaq Capital Market Indic

Filing Documents

• tm254832d1_8k.htm (8-K) — 29KB
• 0001104659-25-007221.txt ( ) — 197KB
• btai-20250128.xsd (EX-101.SCH) — 3KB
• btai-20250128_lab.xml (EX-101.LAB) — 33KB
• btai-20250128_pre.xml (EX-101.PRE) — 22KB
• tm254832d1_8k_htm.xml (XML) — 3KB

07. Submission

Item 5.07. Submission of Matters to a Vote of Security Holders. On January 28, 2025, BioXcel Therapeutics, Inc. (the "Company") held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, a total of 30,360,492 shares of common stock were present in person or represented by proxy at the meeting, representing approximately 61.17% of the Company's outstanding common stock as of the December 17, 2024 record date. The following are the voting results for the proposals considered and voted upon at the meeting, each of which were described in the Company's definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on December 30, 2024. Proposal 1 — Approval of an amendment to the Company's Certificate of Incorporation, as amended, to effect a reverse stock split of the Company's common stock at a ratio in the range of 1-for-5 to 1-for-30 to be determined at the discretion of the Company's Board of Directors. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 27,561,658 2,516,377 282,457 N/A Proposal 2 — Approval of an adjournment of the Special Meeting to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve Proposal 1. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 27,740,608 2,466,032 153,852 N/A Based on the foregoing, Proposal 1 was approved, and adjournment of the Special Meeting was not necessary or appropriate because there were sufficient votes in favor of Proposal 1.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOXCEL THERAPEUTICS, INC. Date: January 29, 2025 By: /s/ Richard Steinhart Richard Steinhart Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR